{"id":"W2897636215","doi":"10.1038/s41375-018-0276-9","title":"Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma","year":2018,"lang":"en","type":"article","venue":"Leukemia","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":117,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency; McMaster University; Juravinski Cancer Centre","funders":"Cilag; Pharmacyclics; H. Lundbeck A/S; Astellas Pharma; Genentech; AstraZeneca; Celgene; Gilead Sciences; GlaxoSmithKline; Amgen","keywords":"Ibrutinib; Bendamustine; Chronic lymphocytic leukemia; Medicine; Internal medicine; Rituximab; Placebo; Ofatumumab; Hazard ratio; Alemtuzumab; Oncology; Lymphoma; Gastroenterology; Leukemia; Confidence interval; Pathology; Transplantation","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001556613,0.0008259388,0.001552242,0.0005381763,0.0003469281,0.0001108343,0.001005819,0.0005355586,0.0002243646],"category_scores_gemma":[0.001645035,0.0006374884,0.0002037024,0.002008992,0.0012109,0.0001813802,0.0007392572,0.0005778529,0.0002958217],"about_ca_system_candidate":true,"about_ca_system_consensus":true,"about_ca_system_score_codex":0.1818926,"about_ca_system_score_gemma":0.07704456,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.059127,"about_ca_topic_score_gemma":0.006888942,"domain_scores_codex":[0.9928102,0.0005350292,0.002108804,0.001708104,0.001360289,0.001477583],"domain_scores_gemma":[0.9942147,0.001540825,0.0006049181,0.002607499,0.000495976,0.0005360444],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.2662329,0.02414969,0.01082603,0.004038943,0.008905026,0.02350876,0.1291145,0.006705713,0.08028851,0.0009821561,0.0889323,0.3563155],"study_design_scores_gemma":[0.6766621,0.006310464,0.007347339,0.00115829,0.0006688796,0.0007119077,0.003499911,0.2848841,0.01407856,0.0001147803,0.003681189,0.000882435],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9925456,0.001667421,0.00002037401,0.0001605224,0.0004892159,0.002681098,0.0002151747,0.000220651,0.001999954],"genre_scores_gemma":[0.9961321,0.0002202248,0.000310316,0.0005169295,0.001263381,0.0001337467,0.0002964688,0.0001590998,0.0009677862],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4104292,"threshold_uncertainty_score":0.9996076,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02888644072565415,"score_gpt":0.3082170913937413,"score_spread":0.2793306506680871,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}